PredOmix, Core Diagnostics Announce Strategic Partnership To Launch OncoVeryx-F
PredOmix Technologies Pvt. Ltd, a health technology pioneer and innovation-driven company, today announced its collaboration with CORE Diagnostics, to launch and market OncoVeryx-F, a cutting-edge multi-cancer early detection (MCED) test specifically designed for cancer screening in high-risk and asymptomatic women.
Identifying cancer at Stage 1 and 2 increases the likelihood of successful treatment
Detecting cancers at an early stage not only allows for prompt interventions but it provides patients with better treatment options, enhancing the chances of successful outcomes and improved quality of life. Early-stage cancers are often localized, making them more amenable to curative treatments such as surgery, radiation therapy, and targeted therapies. OncoVeryx-F, a proprietary test developed by PredOmix, is set to transform early-stage cancer detection and improve treatment outcomes. The test’s ability to identify cancer even at Stage 1 and 2 increases the likelihood of successful treatment, providing patients a better chance of recovery. With an impressive accuracy rate of 98%, OncoVeryx-F can screen for the presence or absence of cancer and accurately identify the Tissue of Origin (TOO) in a single test. Moreover, the test offers a major advantage as it can be performed using a simple blood sample, providing a convenient and non-invasive screening method for individuals. This breakthrough technology offers a comprehensive screening solution for four cancers, including breast, endometrial, cervical, and ovarian cancer.
Cancer Diagnosis at an early stage provides better treatment
PredOmix’s Dr. Kanury Rao says, early cancer detection is what saves lives. “OncoVeryx-F is a simple blood test that looks for cancer metabolic signatures in the bloodstream” Dr. Rao says. “This test is very significant for women. We have developed this test for early detection, so we can diagnose cancer earlier and so treatment can begin earlier and avoid some of the long-term problems and help women live longer. Together with Core Diagnostics, we aim to reduce the number of advanced cancers in the country”.
“We are thrilled to collaborate with PredOmix to bring OncoVeryx-F to the market,” said Mr Dinesh Chauhan, CEO of CORE Diagnostics. “This ground-breaking multi-cancer detection test represents a significant advancement in early-stage cancer diagnosis. By combining the expertise of PredOmix with our commitment to improving patient outcomes, we aim to make a tangible difference in the lives of women at high risk for cancer.”
Experiencing Frequent Yawning? Here Are Five Potential Health Concerns Associated With It | ALSO READ
CORE Diagnostics is a rapidly expanding
CORE Diagnostics is a rapidly expanding and leading clinical diagnostic laboratory in India, renowned for its specialization and expertise in the field of oncology. With a focus on delivering high-end diagnostic and genetic services, CORE Diagnostics is actively working to expand its presence beyond India and establish itself in countries across Asia, the Middle East, and Africa. CORE Diagnostics established its first lab in 2012 at Gurugram, which is NABL & CAP accredited. They have a team of 600 personnel committed to providing high-quality reports to patients. They currently have over 8500 prescribers and over 1000 clients, which include Hospitals, Clinics, Diagnostic Laboratories, NGOs, Pharmaceutical Companies, State Governments, and many more.
The launch of OncoVeryx-F is scheduled for July 15th, 2023, marking a milestone in the fight against cancer. This collaboration between PredOmix and CORE Diagnostics signifies a shared commitment to leveraging advanced technologies to enhance preventive healthcare and early-stage disease diagnosis.
President Smt Droupadi Murmu Presides over AGM of the Indian Red Cross Society | ALSO READ